title: Acetylation control of the retinoblastoma tumour-suppressor protein.
abstract: The retinoblastoma tumour-suppressor protein (pRb) and p300/CBP co-activator proteins are important for control of proliferation and in tumour cells these are sequestered by viral oncoproteins such as E1A. pRb is involved in negatively regulating growth, and p300/CBP proteins have histone acetyltransferase (HAT) activity, which influences gene expression. Although it is known that phosphorylation by G1 cyclin-dependent kinases (CDKs) regulates pRb activity, the nature and role of other post-translational modifications is not understood. Here we identify acetylation as a new type of modification and level of control in pRb function. Adenovirus E1A, which binds p300/CBP through an amino-terminal transformation-sensitive domain, stimulates the acetylation of pRb by recruiting p300 and pRb into a multimeric-protein complex. Furthermore, pRb acetylation is under cell-cycle control, and acetylation hinders the phosphorylation of pRb by cyclin-dependent kinases. pRb binds more strongly when acetylated to the MDM2 oncoprotein, which indicates that acetylation may regulate protein-protein interactions in the pRb pathway. The acetylation of pRb defines a new level of cell-cycle control mediated by HAT. Furthermore, our results establish a relationship between p300, pRb and acetylation in which E1A acts to recruit and target a cellular HAT activity to pRb.
authors: Division of Biochemistry and Molecular Biology, Davidson Building, University of Glasgow, Glasgow G12 8QQ, UK.
authors: H M
authors: HM
authors: Chan
authors: M
authors: M
authors: Krstic-Demonacos
authors: L
authors: L
authors: Smith
authors: C
authors: C
authors: Demonacos
authors: N B
authors: NB
authors: La Thangue
mesh_terms: D000107:Acetylation / Q000187:drug effects; D017500:Adenovirus E1A Proteins / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D006131:Growth Inhibitors / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D009154:Mutation; D009687:Nuclear Proteins / Q000494:pharmacology; D011485:Protein Binding; D011499:Protein Processing, Post-Translational; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2; D016160:Retinoblastoma Protein / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D015534:Trans-Activators / Q000494:pharmacology; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D017500:Adenovirus E1A Proteins; D006131:Growth Inhibitors; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016160:Retinoblastoma Protein; D015534:Trans-Activators; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2